Trial reportSurgical endoscopy2023
Endoscopic ultrasonography-guided injection of cyanoacrylate in the treatment of gastroesophageal varices type 1: a single-center randomized study.
Trial report in Surgical endoscopy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 13 citations in OpenAlex.
- The efficacy and safety of endoscopic ultrasound selective variceal devascularization for the treatment of esophagogastric varices: a retrospective cohort study.BMC gastroenterology · 2026Article
- Direct venous-to-arterial communication as a novel mechanism for ectopic embolism following esophageal variceal embolization: A case report.Experimental and therapeutic medicine · 2026Article
- Determinants and cost composition of hospitalization for EGVB in decompensated cirrhosis.BMC gastroenterology · 2026Article
- A Technical Review of EUS-Guided Variceal Eradication.Clinical and translational gastroenterology · 2026Review
- EUS-guided esophagogastric variceal obliteration: real-world cohort of three generation glue embolization (with video).Surgical endoscopy · 2026Article
- Endoscopic ultrasonography-guided cyanoacrylate injection versus endoscopic cyanoacrylate injection for treating isolated gastric varices type 1 bleeding with spontaneous shunts: a randomized controlled trial.Therapeutic advances in gastroenterology · 2026Article
- Cyanoacrylate injection assisted by endosonographic mini-probe in the management of gastric varices: a single-center, retrospective cohort study.Surgical endoscopy · 2025Article
- Advances in the diagnosis and management of clinically significant portal hypertension in cirrhosis: A narrative review.World journal of hepatology · 2025Review
- Endoscopic ultrasound-guided therapies versus retrograde transvenous obliteration for gastric varices: Multicenter propensity matched analysis.Endoscopy international open · 2025Article
- Comprehensive approach to esophageal variceal bleeding: From prevention to treatment.World journal of gastroenterology · 2024Article
- Endoscopic ultrasound-guided vascular interventions: A review (with videos).Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024Review
- EUS-Guided Vascular Interventions: Recent Advances.Journal of clinical medicine · 2024Review
- Endoscopic ultrasound in portal hypertension: navigating venous hemodynamics and treatment efficacy.Gastroenterology report · 2024Review
- EUS-guidedEndoscopic ultrasoundReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimFirst, it has been demonstrated that endoscopic ultrasonography (EUS)-guided cyanoacrylate (CYA) injection (EUS-CYA) has greater efficacy than direct endoscopic injection of cyanoacrylate (DEI-CYA) for treating type 1-isolated gastric varices. However, it is necessary to conduct further studies to determine whether EUS has any advantage over the current guidelines for treating gastroesophageal varices type 1 (GOV1). Second, liver function is an important prognostic factor in patients with liver cirrhosis. Therefore, we evaluated the liver function of patients treated with EUS-CYA.
methodsIn a single-center study, a prospective cohort from February 2021 to September 2022 involving 89 patients with cirrhosis with GOV1 were assigned to undergo EUS-CYA (n = 45) or DEI-CYA (n = 44). The success rate of CYA injection, the rate of overall rebleeding, the rate of reintervention, the complications during the follow-up period, and the liver function were compared.
resultsIn both groups, 100% of the operations were successful. The follow-up time of the two groups was 290 (153-398) days and 267 (177-416) days, respectively. In the EUS group, the perforating veins had an average diameter of 7.0 ± 2.7 mm, and they had a 100% occlusion rate. A statistically significant difference was found between the two groups regarding the number of sessions needed to eradicate GV (p = 0.005, pairwise comparisons were conducted using the Bonferroni correction method.), the late rebleeding rate after EUS-CYA [n = 3 (6.7%) vs n = 10 (22.7%); p = 0.032], and the incidence of postinjection ulcers [n = 4 (8.9%) vs n = 12 (27.3); p = 0.023)]. Following EUS or DEI-CYA treatment, the patient's liver function did not show any significant deterioration or decline.
conclusionEUS-CYA has a higher eradication success rate and fewer complications, recurrences, and rebleeding episodes than DEI-CYA used for GOV1 treatment. In addition, EUS-CYA did not impair liver function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.